CoChat
Sign Up
Cited by 186

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Immune dysregulation in cancer patients developing immune-related adverse events

Khan, Shaheen, Khan, Saad A., Luo, Xin, Fattah, Farjana J., Saltarski, Jessica, Gloria-McCutchen, Yvonne, Lu, Rong, Xie, Yang, Li, Quan, Wakeland, Edward, Gerber, David E.·2019·British Journal of Cancer
DOI 10.1038/s41416-018-0155-1PMC PMC6325132
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-018-0155-1

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 6 references

Research works printed but not linked: 24

  1. Gonzalez-Rodriguez, E. & Rodriguez-Abreu, D., & Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21, 804–816 (2016). · DOI
  2. Horvat, T. Z. et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33, 3193–3198 (2015). · DOI · Paper page
  3. Manson, G., Norwood, J., Marabelle, A., Kohrt, H. & Houot, R. Biomarkers associated with checkpoint inhibitors. Ann. Oncol. 27, 1199–1206 (2016). · DOI
  4. Khan, S. A., Pruitt, S. L., Xuan, L. & Gerber, D. E. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2, 1507–1508 (2016). · DOI
  5. Khan, S. A., Pruitt, S. L., Xuan, L., Makris, U. & Gerber, D. E. How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. Lung Cancer 115, 97–102 (2018). · DOI
  6. Zandman-Goddard, G. & Shoenfeld, Y. HIV and autoimmunity. Autoimmun. Rev. 1, 329–337 (2002). · DOI
  7. Rotondi, M., Chiovato, L., Romagnani, S., Serio, M. & Romagnani, P. Role of chemokines in endocrine autoimmune diseases. Endocr. Rev. 28, 492–520 (2007). · DOI
  8. Marshall, A., Celentano, A., Cirillo, N., McCullough, M. & Porter, S. Tissue-specific regulation of CXCL9/10/11 chemokines in keratinocytes: Implications for oral inflammatory disease. PLoS ONE 12, e0172821 (2017). · DOI
  9. Magliozzi, R. et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130, 1089–1104 (2007). · DOI
  10. Henneken, M., Dorner, T., Burmester, G. R. & Berek, C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res. Ther. 7, R1001–R1013 (2005). · DOI
  11. Barone, F. et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren’s syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J. Immunol. 180, 5130–5140 (2008). · DOI
  12. Armengol, M. P. et al. Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4+ T and CCR7 B and T lymphocytes in thyroid autoimmune diseases. J. Immunol. 170, 6320–6328 (2003). · DOI
  13. Rioja, I. et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 58, 2257–2267 (2008). · DOI
  14. Meraouna, A. et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108, 432–440 (2006). · DOI
  15. Tokunaga, R. et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat. Rev. 63, 40–47 (2018). · DOI · Paper page
  16. Akeus, P. et al. Treg-cell depletion promotes chemokine production and accumulation of CXCR3(+) conventional T cells in intestinal tumors. Eur. J. Immunol. 45, 1654–1666 (2015). · DOI
  17. Gorbachev, A. V. et al. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J. Immunol. 178, 2278–2286 (2007). · DOI
  18. Mlecnik, B. et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138, 1429–1440 (2010). · DOI
  19. Bedognetti, D. et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br. J. Cancer 109, 2412–2423 (2013). · DOI
  20. Haratani, K. et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 4, 374–378 (2018). · DOI · Paper page
  21. Yamazaki, N. et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Sci. 108, 1022–1031 (2017). · DOI
  22. Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015). · DOI · Paper page
  23. Kantola, T. et al. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br. J. Cancer 107, 1729–1736 (2012). · DOI
  24. Blogowski, W. et al. Selected cytokines in patients with pancreatic cancer: a preliminary report. PLoS ONE 9, e97613 (2014). · DOI

Cited by

Sorted by citations

See all 186

Metadata

Authors
Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J., Gloria-McCutchen, Y., Lu, R., Xie, Y., Li, Q., Wakeland, E., & Gerber, D. E.
Venue
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Published
2018-10-31
Volume
120
Issue
1
Pages
63-68
ISSN
  • 0007-0920
  • 1532-1827
DOI
10.1038/s41416-018-0155-1
PMC
PMC6325132
Cited by
186
References
6
Language
en
Licence
creativecommons.org/licenses/by/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review